Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron develops new product candidate using VelociSuite technology platforms. Regeneronís discovery platforms are designed to identify specific proteins of therapeutic interest for a particular disease or cell type and validate these targets through high-throughput production of genetically modified mice using the Companyís VelociGene technology to understand the role of these proteins in normal physiology, as well as in models of disease. The Company also has human monoclonal antibody technology, VelocImmune and cell line expression technology VelociMab. Regeneronís antibody product candidates in clinical trials were developed using VelocImmune. The Company has three marketed products: EYLEA, ZALTRAP and ARCALYST.

Official website: www.regeneron.com